Physician profile
Robert T Mcmahon
NPI 1750362422
$1,506.59
in general payments reported to CMS, 2019-2025
14 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $56.40 · 2021: $16.75 · 2023: $125 · 2024: $758 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699 · Debt Forgiveness: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.92 |
| Debt Forgiveness | $465.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $553.03 | 2019-2024 | Panoramic Ophthalmoscope |
| Bausch & Lomb Americas INC. | $250.01 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $124.68 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $124.21 | 2024 | |
| Abbvie INC. | $113.47 | 2025 | |
| Sun Pharmaceutical Industries INC. | $87.90 | 2019-2020 | |
| Allergan, INC. | $86.93 | 2019 | |
| Rxsight INC | $43.56 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Carl Zeiss Meditec USA, INC. | $42.99 | 2024 | Iolmaster 700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.54 | 2020 | |
| Ocular Therapeutix, INC. | $16.75 | 2021 | |
| Eyepoint US, INC. | $11.48 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.